Commentary

Need for more data


 

References

There was general consensus among panel members that no single approach to postmarketing safety studies would likely be sufficient to evaluate new or existing products, and that complementary approaches are needed.

A complete set of the panelists’ slide presentations from the public meeting as well as webcasts of the 2-day proceedings in their entirety are available for viewing here.

Dr. Chambers is a professor of pediatrics and director of clinical research at Rady Children’s Hospital, and associate director of the Clinical and Translational Research Institute at the University of California, San Diego. She is director of MotherToBaby California, a past president of the Organization of Teratology Information Specialists, and past president of the Teratology Society. She said that she had no relevant financial disclosures. To comment, e-mail her at obnews@frontlinemedcom.com.

Pages

Recommended Reading

Birth defect risk low in celiac disease
MDedge Internal Medicine
Azathioprine, anti-TNF monotherapy safe in IBD pregnancy
MDedge Internal Medicine
Live births seen in half of pregnancies exposed to belimumab
MDedge Internal Medicine
Supreme Court: Companies can deny contraceptive coverage
MDedge Internal Medicine
Donated IVF eggs linked to gestational hypertension
MDedge Internal Medicine
Sleep apnea raises cardiomyopathy risk ninefold in pregnancy
MDedge Internal Medicine
As severity of rheumatoid arthritis rises, so does risk of preterm delivery
MDedge Internal Medicine
Prenatal exposure to alcohol can result in persistent difficulties with math
MDedge Internal Medicine
Pregnancy exposure registries confirmed useful in assessing product safety
MDedge Internal Medicine
Births to unmarried women down since 2008
MDedge Internal Medicine